Search Results - "Mandala, Eudokia M."

Evaluation of treatment with bosentan in patients with carcinoid heart disease: single center study by Lafaras, Christos T, Mandala, Eudokia M, Platogiannis, Dimitrios N, Saratzis, Athanasios N, Barbetakis, Nikolaos G, Paraskevopoulos, Panagiotis P, Ilonidis, George C, Bischiniotis, Theodoros S

“…The primary aim of this study was to evaluate a combined therapeutic intervention, including the dual endothelin receptor antagonist bosentan, in patients with…”
Get more information

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome (aHUS), Treated with Eculizumab by Mandala, Eudokia M., Gkiouzepas, Spyridon, Kasimatis, Efstratios, Lafaras, Christos, Chalevas, Parthenis, Tsioni, Konstantina, Kyrka, Krystallia, Oikonomidou, Dominiki, Dinas, Konstantinos, Loufopoulos, Aristotelis, Efstratiadis, George, Vasilia, Garipidou, Garyfallos, Anastasios-Alexandros

“…Introduction:aHUS is a life-threatening, chronic, progressive disease of complement mediated thrombotic microangiopathy (TMA), commonly associatedwith…”
Get full text

The Clinical Utility Of Bone Turnover Markers In The Evaluation Of Bone Disease In Patients With Haemophilia A and B by Anagnostis, Panagiotis, Vakalopoulou, Sofia, Timoleon-Achilleas, Vyzantiadis, Charizopoulou, Maria, Mandala, Eudokia M., Agapidou, Alexandra, Vassiliki, Violaki, Vasilia, Garipidou

“…Hemophilia A and B has been associated with increased prevalence of low bone mineral density (BMD). However, the utility of bone turnover markers (BTM) is…”
Get full text

Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents by Symeonidis, Argiris S., Kastritis, Efstathios, Delimpasi, Sosana, Kelaidi, Charikleia, Sioni, Anastasia, Michael, Michalis, Vassou, Amalia, Christoforidou, Anna, Repousis, Panagiotis, Mandala, Eudokia M., Terpos, Evangelos, Dimopoulos, Meletios A.

“…Multiple myeloma (MM) is a disease of the elderly and the median age at diagnosis is 65 to 68 years; MM is rarely diagnosed in patients ≤40 years of age…”
Get full text

IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents by Zagouri, Flora, Kastritis, Efstathios, Symeonidis, Argiris S., Giannakoulas, Nikolaos, Katodritou, Eirini, Delimpasi, Sosana, Repousis, Panagiotis, Giannouli, Stavroula, Mandala, Eudokia M., Terpos, Evangelos, Dimopoulos, Meletios A.

“…IgD multiple myeloma is a rare variant of the disease and in various series accounts for about 2% of patients with symptomatic myeloma. It has been suggested…”
Get full text